Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Lyndsay N. Harris, Gerald Batist, Robert J. Belt, +5

Cancer

Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma

Richard F. Little, Kathleen M. Wyvill, James M. Pluda, +10

Journal of Clinical Oncology

Primary ImmunodeficiencyMedian Thalidomide DoseOncologyMedicineMetronomic Therapy +10

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.

Lauri Welles, M. Wayne Saville, Jill Lietzau, +14

Journal of Clinical Oncology

Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

Christine E. Swenson, Lois E. Bolcsak, Gerald Batist, +7

Anti-Cancer Drugs

Developing Drugs to Decrease the Toxicity of Chemotherapy

Grant Williams, Patricia Cortazar, Richard Pazdur, +2

Journal of Clinical Oncology

MedicineMetronomic TherapyPharmacologyAntitumor EfficacySingle-agent Doxorubicin +11

A Pilot Study of Cidofovir in Patients with Kaposi Sarcoma

Richard F. Little, Florentino Merced‐Galindez, Katherine Staskus, +11

The Journal of Infectious Diseases

Kaposi SarcomaHuman RetrovirusImmunologyAntiviral TherapyPathology +9

Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response

Alexandra M. Levine, Anil Tulpule, Byron M. Espina, +5

Journal of Clinical Oncology

Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer

Charles L. Shapiro, T.J. Ervin, Lauri Welles, +3

Journal of Clinical Oncology

Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies

H. S. Hochster, Lauri Welles, L. Hart, +7

Journal of Clinical Oncology

Cancer ManagementPathologyBowel PerforationFirst-line TreatmentPharmacotherapy +15

Phase I/II Trial of Nonpegylated Liposomal Doxorubicin, Cyclophosphamide, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Anil Tulpule, Byron M. Espina, Nancy E.J. Berman, +9

Clinical Lymphoma & Myeloma

Lymphoid NeoplasiaAggressive Non-hodgkinNonpegylated Liposomal DoxorubicinMedicineMalignant Blood Disorder +7